[go: up one dir, main page]

WO2013100660A3 - Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물 - Google Patents

Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물 Download PDF

Info

Publication number
WO2013100660A3
WO2013100660A3 PCT/KR2012/011631 KR2012011631W WO2013100660A3 WO 2013100660 A3 WO2013100660 A3 WO 2013100660A3 KR 2012011631 W KR2012011631 W KR 2012011631W WO 2013100660 A3 WO2013100660 A3 WO 2013100660A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye
pharmaceutical composition
treatment
synthesis inhibitor
pge2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/011631
Other languages
English (en)
French (fr)
Other versions
WO2013100660A2 (ko
Inventor
이형근
심종우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120074204A external-priority patent/KR101373246B1/ko
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Priority to US14/648,970 priority Critical patent/US9629855B2/en
Priority to JP2014550020A priority patent/JP5870211B2/ja
Publication of WO2013100660A2 publication Critical patent/WO2013100660A2/ko
Publication of WO2013100660A3 publication Critical patent/WO2013100660A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 PGE2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 PGE2 합성 억제제를 유효성분으로 포함하는 안구 통증 예방 또는 치료용 약학 조성물을 이용하면 PGE2의 발현 수준을 선택적으로 억제시킴으로써 안구 통증 증상을 호전시킬 수 있고, 나아가 안구건조증의 치료 및 예방, 수술 후 상태 등의 다양한 염증 발현 상황에 의한 안구 불편감 해소 및 예방에 효과가 있다. 또한, PGE2, PGD2 및 COX2의 양을 검출하는 키트를 이용하여 임상에서 손쉽게 안구 통증 증상을 진단할 수 있어 안구건조증 환자 뿐만 아니라 안 수술 후 환자의 상태를 파악하는 데 널리 활용될 수 있다.
PCT/KR2012/011631 2011-12-29 2012-12-27 Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물 Ceased WO2013100660A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/648,970 US9629855B2 (en) 2011-12-29 2012-12-27 Pharmaceutical composition for treatment of eye pain, containing PGE2 synthesis inhibitor
JP2014550020A JP5870211B2 (ja) 2011-12-29 2012-12-27 Ｐｇｅ２合成抑制剤を含む眼球痛症治療用薬学組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0146450 2011-12-29
KR20110146450 2011-12-29
KR10-2012-0074204 2012-07-06
KR1020120074204A KR101373246B1 (ko) 2011-12-29 2012-07-06 Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
WO2013100660A2 WO2013100660A2 (ko) 2013-07-04
WO2013100660A3 true WO2013100660A3 (ko) 2013-10-03

Family

ID=48698750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/011631 Ceased WO2013100660A2 (ko) 2011-12-29 2012-12-27 Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물

Country Status (1)

Country Link
WO (1) WO2013100660A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968566B2 (en) 2014-08-28 2018-05-15 Keio University Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US20110281882A1 (en) * 2007-08-10 2011-11-17 Jinzhong Zhang Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US20110281882A1 (en) * 2007-08-10 2011-11-17 Jinzhong Zhang Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BHATTACHERJEE, P. ET AL.: "Inhibition of the prostaglandin synthetase systems in ocular tissues by indomethacin", BR. J. PHARMAC., vol. 50, 1974, pages 227 - 230 *
CHO, HYUNG ET AL.: "Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution", CLINICAL OPHTHALMOLOGY, vol. 3, 2009, pages 199 - 210 *
KULKARNI, P. S. ET AL.: "The effect of intravitreal and topical prostaglandins on intraocular inflammation", INVEST, OPHTHAMOL. VIS. SCI., vol. 23, no. 3, 1982, pages 383 - 392 *

Also Published As

Publication number Publication date
WO2013100660A2 (ko) 2013-07-04

Similar Documents

Publication Publication Date Title
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
EA202091999A3 (ru) Применение ингибиторов dpp iv
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
AR086395A1 (es) Envase para el tratamiento de patologias
MX2009011900A (es) Curacion de herida diabetica.
WO2008031835A3 (en) Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
EA201270449A1 (ru) Фармацевтическая композиция для лечения связанных с мср-1 воспалительных заболеваний
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
ECSP088588A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
EP4218786A3 (en) Opiorphin for use as analgesic agent
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
WO2013100660A3 (ko) Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12863025

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014550020

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 12863025

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14648970

Country of ref document: US